Indian branded-generics maker best known for anti-infective drugs, with a growing US generics and biosimilars business.
Indian branded-generics maker best known for anti-infective drugs, with a growing US generics and biosimilars business.
Earns most of its sales from branded medicines in India, sold through a very large field force of representatives to doctors and wholesalers, with anti-infectives and chronic treatments leading. The US generics arm and the biosimilar unit Enzene add exports. The founding Singh family controls it.
In one line: India's mid-cap generics maker with a biosimilar arm.
Moat: narrow (brand, distribution). Leading anti-infective brand (Clavam) and one of India's largest pharma sales forces.
Headquarters: Mumbai, India · Founded: 1973 · Employees: 23,386
Size Alkem Laboratories (ALKEM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $6.69B, the 172nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹5,222 on 18 Nov 2026.
Performance Over six months the shares fell 4.5%, against -1.8% for the median peer and +3.8% for the India market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 12.5% over the last twelve months (peer median +16.4%); the operating margin is 17.3% (peer median 13.8%).
Valuation It trades at 27.3× forward earnings against a peer median of 17.3× (4th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.8 points below its cost of capital (12.5% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹156B | ₹147B | ₹129B | ₹126B | ₹116B |
| Revenue growth | — | +13% | +3% | +8% | — |
| Gross profit | ₹68.4B | ₹57.9B | ₹48.4B | ₹46.4B | ₹37.6B |
| EBITDA | ₹31.4B | ₹30.8B | ₹25.4B | ₹22.5B | ₹16.8B |
| Net income | ₹20.7B | ₹23.0B | ₹21.7B | ₹18.0B | ₹9.84B |
| Free cash flow | n/a | ₹15.5B | ₹15.0B | ₹18.4B | ₹15.1B |
| Capital expenditure | n/a | ₹6.17B | ₹6.76B | ₹2.59B | ₹2.33B |
| Total debt | ₹23.1B | ₹20.5B | ₹13.8B | ₹14.2B | ₹14.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alkem Laboratories ALKEM.NS | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% |
| Mankind Pharma MANKIND.NS | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Torrent Pharmaceuticals TORNTPHARM.NS | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALKEM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.4% | -0.7% | 8th highest of 21 |
| 6-month return | -4.5% | -1.8% | 10th lowest of 20 |
| Distance from 52-week high | -12.0% | -25.4% | 7th highest of 21 |
| Revenue growth (TTM) | +12.5% | +16.4% | 9th lowest of 18 |
| Operating margin | 17.3% | 13.8% | 6th highest of 19 |
| Forward P/E | 27.3× | 17.3× | 4th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 25.0% | 3.6% | 2nd most demanding of 11 |
| Growth delivered (Del g) | +10.7% | +12.3% | 5th lowest of 11 |
| Hurdle (Req g minus delivered) | +14.3 pp | -12.7 pp | 2nd most demanding of 11 |
| ROIC minus cost of capital | -0.8 pp | +1.9 pp | 9th lowest of 18 |
| EV / EBITDA | 20.5× | 21.0× | 5th cheapest of 10 |
| Net debt / EBITDA | 0.3× | 0.8× | 4th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% | +303.3% |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |